Hansen Medical to Exhibit Magellan(TM) Robotic System at 2013 Vascular Annual Meeting(R) of the Society for Vascular Surgery

Hansen Medical to Exhibit Magellan(TM) Robotic System at 2013 Vascular Annual 
Meeting(R) of the Society for Vascular Surgery 
MOUNTAIN VIEW, CA -- (Marketwired) -- 05/23/13 --  Hansen Medical,
Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today
announced that it will exhibit its Magellan(TM) Robotic System at the
2013 Vascular Annual Meeting(R) of the Society for Vascular Surgery
from May 30 - June 1 at the Moscone West Convention Center in San
Francisco, CA. The Company will be exhibiting the Magellan Robotic
System and conducting product demonstrations at Booth 301. 
"We are excited to showcase our Magellan Robotic System at this
important annual meeting of leading vascular surgeons," said Bruce
Barclay, President and CEO of Hansen Medical. "Based on the over 150
vascular cases that have now been performed to date, as well as the
feedback received from clinicians worldwide and the extensive
pre-clinical work previously completed, we are confident that this
product has the potential to enhance the way physicians navigate the
vasculature. The Magellan Robotic System and Catheter give physicians
maximum flexibility and control through independent distal tip
control of a catheter and a sheath, as well as through robotic
manipulation of a standard guidewire from a centralized, remote
workstation. Moreover, this proprietary technology is designed to
deliver predictable catheter navigation of peripheral vessels." 
About the Magellan(TM) Robotic System 
Hansen Medical's Magellan Robotic System is based upon the flexible
robotic technology incorporated in the Sensei-X(R) Robotic Catheter
System currently sold in the U.S. and Europe, which has been used in
over 10,000 patients, but includes a number of key enhancements. In
particular, the Magellan Robotic System: 

--  Provides solid catheter stability for placement of therapeutic
--  Is designed to enable predictable procedure times and increased case
--  Allows for independent, individual robotic control of the distal tips
    of both the outer sheath and the inner leader catheter, as well as
    robotic manipulation of standard guidewires.
--  Is designed to allow for sufficient extension inside the body to
    access hard to reach peripheral anatomy.
--  Preserves the open architecture featured in the Sensei System to allow
    for the subsequent use of many 6F therapeutic devices on the market
--  Is designed to potentially reduce physician radiation exposure and
    fatigue by employing a remote physician workstation.

About Hansen Medical, Inc.  
Hansen Medical, Inc., based in Mountain View, California, is the
global leader in intravascular robotics, developing products and
technology designed to enable the accurate positioning, manipulation
and control of catheters and catheter-based technologies. The
Company's Magellan(TM) Robotic System, NorthStar(TM) Robotic Catheter
and related accessories, which are intended to facilitate navigation
to anatomical targets in the peripheral vasculature and subsequently
provide a conduit for manual placement of therapeutic devices, have
undergone both CE marking and 510(k) clearance and are commercially
available in the European Union, and the U.S. In the European Union,
the Company's Sensei(R) X Robotic Catheter System and Artisan Control
Catheter are cleared for use during electrophysiology (EP)
procedures, such as guiding catheters in the treatment of atrial
fibrillation (AF), and the Lynx(R) Robotic Ablation Catheter is
cleared for the treatment of AF. This robotic catheter system is
compatible with fluoroscopy, ultrasound, 3D surface map and patient
electrocardiogram data. In the U.S. the Company's Sensei X Robotic
Catheter System and Artisan Control Catheter were cleared by the U.S.
Food and Drug Administration for manipulation and control of certain
mapping catheters in EP procedures. In the United States, the Sensei
System is not approved for use in guiding ablation procedures; this
use remains experimental. The U.S. product labeling therefore
provides that the safety and effectiveness of the Sensei X System and
Artisan Control Catheter for use with cardiac ablation catheters in
the treatment of cardiac arrhythmias, including AF, have not been
established. Additional information can be found at
Forward-Looking Statements  
This press release contains forward-looking statements regarding,
among other things, statements relating to goals, plans, objectives,
milestones and future events. All statements, other than statements
of historical fact, are statements that could be deemed
forward-looking statements, including statements containing the words
"plan," "expects," "potential," "believes," "goal," "estimate,"
"anticipates," and similar words. These statements are based on the
current estimates and assumptions of our management as of the date of
this press release and are subject to risks, uncertainties, changes
in circumstances and other factors that may cause actual results to
differ materially from the information expressed or implied by
forward-looking statements made in this press release. Examples of
such statements include statements about the potential benefits of
our Magellan Robotic System for hospitals, patients and physicians,
and the anticipated timing of commercially launching a 6F vascular
catheter. Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements
include, among others: engineering, regulatory, manufacturing, sales
and customer service challenges in developing new products and
entering new markets; the commercial viability of our products in the
vascular markets; potential safety and regulatory issues that could
slow or suspend our sales; the effect of economic conditions on
capital spending by our potential customers; the uncertain timelines
for the sales cycle for newly introduced products; the rate of
adoption of our systems and the rate of use of our catheters; the
scope and validity of intellectual property rights applicable to our
products; competition from other companies; our ability to recruit
and retain key personnel; our ability to maintain our remedial
actions over previously reported material weaknesses in internal
controls over financial reporting; our ability to manage expenses and
cash flow, and obtain additional financing; and other risks more
fully described in the "Risk Factors" section of our Quarterly Report
on Form 10-Q for the quarter ended March 31, 2013 filed with the SEC
on May 10, 2013 and the risks discussed in our other reports filed
with the SEC. Given these uncertainties, you should not place undue
reliance on the forward-looking statements in this press release. We
undertake no obligation to revise or update information herein to
reflect events or circumstances in the future, even if new
information becomes available.  
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan is a
trademark of Hansen Medical, Inc. in the United States and other
countries. Vascular Annual Meeting is a registered trademark of the
Society for Vascular Surgery. 
Investor Contacts: 
Peter J. Mariani 
Chief Financial Officer 
Hansen Medical, Inc. 
FTI Consulting, Inc.
Brian Ritchie
John Capodanno
Press spacebar to pause and continue. Press esc to stop.